Background: A number of benzimidazole derivatives such as benomyl and carbendazim have been
known for their potential role as agricultural fungicides. Simultaneously carbendazim has also been found to
inhibit proliferation of mammalian tumor cells specifically drug and multidrug resistant cell lines.
Objective: To understand the dual role of Carbendazim as a fungicide and an anticancer agent, the study has been
planned referring to the earlier studies in literature.
Results: Studies carried out with fungal and mammalian cells have highlighted the potential role of carbendazim in
inhibiting proliferation of cells, thereby exhibiting therapeutic implications against cancer. Because of its
promising preclinical antitumor activity, Carbendazim had undergone phase I clinical trials and is under further
clinical investigations for the treatment of cancer. A number of theoretical interactions have been pinpointed.
There are many anticancer drugs in the market, but their usefulness is limited because of drug resistance in a
significant proportion of patients. The hunger for newer drugs drives anticancer drug discovery research on a
global platform and requires innovations to ensure a sustainable pipeline of lead compounds.
Conclusion: Current review highlights the dual role of carbendazim as a fungicide and an anticancer agent.
Further, the harmful effects of carbendazim and emphasis upon the need for more pharmacokinetic studies and
pharmacovigilance data to ascertain its clinical significance, have also been discussed.